Published in Clin Cancer Res on July 05, 2012
Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Solid Cancer | NCT00582985
In vivo tumor targeting and image-guided drug delivery with antibody-conjugated, radiolabeled mesoporous silica nanoparticles. ACS Nano (2013) 1.34
Tumor vasculature targeting and imaging in living mice with reduced graphene oxide. Biomaterials (2013) 1.26
Understanding and targeting resistance to anti-angiogenic therapies. J Gastrointest Oncol (2013) 1.05
PET imaging of CD105/endoglin expression with a ⁶¹/⁶⁴Cu-labeled Fab antibody fragment. Eur J Nucl Med Mol Imaging (2013) 1.03
Endoglin requirement for BMP9 signaling in endothelial cells reveals new mechanism of action for selective anti-endoglin antibodies. PLoS One (2012) 1.01
Improved survival outcomes in cancer patients with hereditary hemorrhagic telangiectasia. Cancer Epidemiol Biomarkers Prev (2013) 1.01
Image-guided and tumor-targeted drug delivery with radiolabeled unimolecular micelles. Biomaterials (2013) 1.00
Engineering of hollow mesoporous silica nanoparticles for remarkably enhanced tumor active targeting efficacy. Sci Rep (2014) 1.00
A lesson for cancer research: placental microarray gene analysis in preeclampsia. Oncotarget (2012) 0.99
Novel therapeutic approaches for the treatment of castration-resistant prostate cancer. J Steroid Biochem Mol Biol (2013) 0.99
Tumor vasculature targeting: a generally applicable approach for functionalized nanomaterials. Small (2014) 0.98
Positron emission tomography imaging of tumor angiogenesis with a (61/64)Cu-labeled F(ab')(2) antibody fragment. Mol Pharm (2013) 0.97
Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy. Front Cell Infect Microbiol (2014) 0.96
In vivo tumor vasculature targeted PET/NIRF imaging with TRC105(Fab)-conjugated, dual-labeled mesoporous silica nanoparticles. Mol Pharm (2014) 0.93
Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer. Clin Cancer Res (2012) 0.92
An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer. Clin Cancer Res (2014) 0.91
Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics. Pharmacol Rev (2013) 0.89
Specific cancer rates may differ in patients with hereditary haemorrhagic telangiectasia compared to controls. Orphanet J Rare Dis (2013) 0.89
Antibody-directed coupling of endoglin and MMP-14 is a key mechanism for endoglin shedding and deregulation of TGF-β signaling. Oncogene (2013) 0.89
Positron emission tomography imaging of CD105 expression in a rat myocardial infarction model with (64)Cu-NOTA-TRC105. Am J Nucl Med Mol Imaging (2013) 0.89
Positron emission tomography imaging of angiogenesis in a murine hindlimb ischemia model with 64Cu-labeled TRC105. Mol Pharm (2013) 0.89
Targeted therapy for renal cell carcinoma: The next lap. J Carcinog (2014) 0.89
Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma. Br J Cancer (2014) 0.87
Theranostic unimolecular micelles based on brush-shaped amphiphilic block copolymers for tumor-targeted drug delivery and positron emission tomography imaging. ACS Appl Mater Interfaces (2014) 0.87
Cancer incidence in patients with hereditary hemorrhagic telangiectasia. J Cancer Res Clin Oncol (2016) 0.87
In Vivo Tumor Vasculature Targeting of CuS@MSN Based Theranostic Nanomedicine. ACS Nano (2015) 0.86
Detailed assessment of microvasculature markers in non-small cell lung cancer reveals potentially clinically relevant characteristics. Virchows Arch (2015) 0.85
Molecular pathways: can activin-like kinase pathway inhibition enhance the limited efficacy of VEGF inhibitors? Clin Cancer Res (2014) 0.85
Imaging tumor angiogenesis in breast cancer experimental lung metastasis with positron emission tomography, near-infrared fluorescence, and bioluminescence. Angiogenesis (2013) 0.85
The angiogenic asset of soft tissue sarcomas: a new tool to discover new therapeutic targets. Biosci Rep (2014) 0.83
New radiotracers for imaging of vascular targets in angiogenesis-related diseases. Adv Drug Deliv Rev (2014) 0.83
Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer. Cancer Med (2014) 0.83
Surface engineering of graphene-based nanomaterials for biomedical applications. Bioconjug Chem (2014) 0.82
Red fluorescent zinc oxide nanoparticle: a novel platform for cancer targeting. ACS Appl Mater Interfaces (2015) 0.82
Effects of the combination of TRC105 and bevacizumab on endothelial cell biology. Invest New Drugs (2014) 0.82
Biomedical applications of functionalized hollow mesoporous silica nanoparticles: focusing on molecular imaging. Nanomedicine (Lond) (2013) 0.81
Reducing endoglin activity limits calcineurin and TRPC-6 expression and improves survival in a mouse model of right ventricular pressure overload. J Am Heart Assoc (2014) 0.80
High Yield Production and Radiochemical Isolation of Isotopically Pure Arsenic-72 and Novel Radioarsenic Labeling Strategies for the Development of Theranostic Radiopharmaceuticals. Bioconjug Chem (2015) 0.80
Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery. Circulation (2015) 0.80
Src-mediated post-translational regulation of endoglin stability and function is critical for angiogenesis. J Biol Chem (2014) 0.80
Gene Electrotransfer of Plasmid with Tissue Specific Promoter Encoding shRNA against Endoglin Exerts Antitumor Efficacy against Murine TS/A Tumors by Vascular Targeted Effects. PLoS One (2015) 0.80
Immuno-PET imaging of tumor endothelial marker 8 (TEM8). Mol Pharm (2014) 0.79
Bio-functionalized dense-silica nanoparticles for MR/NIRF imaging of CD146 in gastric cancer. Int J Nanomedicine (2015) 0.78
Facilitation of endoglin-targeting cancer therapy by development/utilization of a novel genetically engineered mouse model expressing humanized endoglin (CD105). Int J Cancer (2014) 0.77
Inhibition of endoglin-GIPC interaction inhibits pancreatic cancer cell growth. Mol Cancer Ther (2014) 0.77
Anti-angiogenesis in prostate cancer: knocked down but not out. Asian J Androl (2014) 0.77
Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins. Biomark Cancer (2016) 0.77
Angiogenesis and lymphangiogenesis in the spectrum of leprosy and its reactional forms. PLoS One (2013) 0.77
Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma. Oncotarget (2016) 0.76
Endoglin targeting inhibits tumor angiogenesis and metastatic spread in breast cancer. Oncogene (2016) 0.76
Targeting Strategies for Renal Cell Carcinoma: From Renal Cancer Cells to Renal Cancer Stem Cells. Front Pharmacol (2016) 0.75
Immuno-expression of endoglin and smooth muscle actin in the vessels of brain metastases. Is there a rational for anti-angiogenic therapy? Int J Mol Sci (2014) 0.75
Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013. Drug Des Devel Ther (2016) 0.75
Endoglin is necessary for angiogenesis in human ovarian carcinoma-derived primary endothelial cells. Cancer Biol Ther (2013) 0.75
Physiologically-based modeling to predict the clinical behavior of monoclonal antibodies directed against lymphocyte antigens. MAbs (2016) 0.75
Microvascular density and immunohistochemical expression of VEGF, VEGFR-1 and VEGFR-2 in benign prostatic hyperplasia, high-grade prostate intraepithelial neoplasia and prostate cancer. Cent European J Urol (2016) 0.75
Targeted therapies for renal cell carcinoma. Nat Rev Nephrol (2017) 0.75
Expression of a novel endothelial marker, C-type lectin 14A, in epithelial ovarian cancer and its prognostic significance. Int J Clin Oncol (2016) 0.75
Targeting angiogenesis for radioimmunotherapy with a (177)Lu-labeled antibody. Eur J Nucl Med Mol Imaging (2017) 0.75
ALK1 signaling in development and disease: new paradigms. Cell Mol Life Sci (2017) 0.75
Endoglin Is Essential for the Maintenance of Self-Renewal and Chemoresistance in Renal Cancer Stem Cells. Stem Cell Reports (2017) 0.75
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol (2009) 14.15
Angiogenesis in health and disease. Nat Med (2003) 14.02
Angiogenesis. J Biol Chem (1992) 11.29
Hereditary hemorrhagic telangiectasia. N Engl J Med (1995) 6.91
Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med (2008) 6.82
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol (2005) 5.27
Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol (2010) 4.43
Defective angiogenesis in mice lacking endoglin. Science (1999) 4.40
Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res (2008) 2.75
CD105 is important for angiogenesis: evidence and potential applications. FASEB J (2003) 2.50
[New guidelines to evaluate the response to treatment in solid tumors]. Bull Cancer (2000) 2.16
Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J Biol Chem (2002) 1.95
Identification of a tumor-initiating stem cell population in human renal carcinomas. FASEB J (2008) 1.88
Positron emission tomography imaging of CD105 expression during tumor angiogenesis. Eur J Nucl Med Mol Imaging (2011) 1.70
Endoglin-targeted cancer therapy. Curr Drug Deliv (2011) 1.65
Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts. Clin Cancer Res (2003) 1.14
Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature. Int J Cancer (2009) 1.03
Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts. Cancer Res (2004) 1.02
Antiangiogenic chimeric anti-endoglin (CD105) antibody: pharmacokinetics and immunogenicity in nonhuman primates and effects of doxorubicin. Cancer Immunol Immunother (2005) 1.01
Differential expression of endoglin on fetal and adult hematopoietic cells in human bone marrow. J Immunol (1995) 1.00
Long-term therapy with bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med (2011) 1.00
Hereditary Haemorrhagic Telangiectasia (HHT): genetic and molecular aspects. Curr Pharm Des (2006) 0.98
Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma. Br J Haematol (2003) 0.95
Expression and structural features of endoglin (CD105), a transforming growth factor beta1 and beta3 binding protein, in human melanoma. Br J Cancer (1996) 0.87
Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status. Tumour Biol (2011) 0.86
Unique aspects of supportive care using monoclonal antibodies in cancer treatment. Support Cancer Ther (2003) 0.83
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 9.05
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol (2003) 8.95
Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res (2002) 4.90
Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol (2002) 4.69
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 4.64
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol (2008) 4.29
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol (2012) 4.19
Pharmacy education: back to the basics? Pharmacotherapy (2003) 4.11
Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol (2005) 4.02
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol (2012) 3.92
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol (2007) 3.91
Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol (2005) 3.79
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol (2008) 3.32
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol (2004) 3.16
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol (2009) 3.13
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.86
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol (2007) 2.80
Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst (2005) 2.74
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood (2011) 2.64
Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol (2007) 2.51
Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res (2010) 2.45
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol (2010) 2.43
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol (2005) 2.36
Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther (2005) 2.23
A randomized clinical trial of methadone maintenance for prisoners: results at 1-month post-release. Drug Alcohol Depend (2007) 2.22
Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res (2007) 2.22
Thalidomide. Lancet (2004) 2.21
A comparison of cognitive-behavioral therapy, sertraline, and their combination for adolescent depression. J Am Acad Child Adolesc Psychiatry (2006) 2.20
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood (2007) 2.15
Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2009) 2.06
A randomized clinical trial of methadone maintenance for prisoners: results at 12 months postrelease. J Subst Abuse Treat (2009) 2.03
Stabilization of Ca2+-permeable AMPA receptors at perisynaptic sites by GluR1-S845 phosphorylation. Proc Natl Acad Sci U S A (2009) 2.00
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol (2005) 1.99
Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin (2010) 1.98
Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol (2003) 1.97
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol (2008) 1.95
Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res (2008) 1.95
Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol (2008) 1.91
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res (2013) 1.90
Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. Proc Natl Acad Sci U S A (2009) 1.89
Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol (2005) 1.88
Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res (2005) 1.88
A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res (2008) 1.87
Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol (2004) 1.85
Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res (2005) 1.84
Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys (2008) 1.83
Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol Pharmacol (2005) 1.81
Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol (2008) 1.74
Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol (2004) 1.73
Validation of analytic methods for biomarkers used in drug development. Clin Cancer Res (2008) 1.73
Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status. J Clin Oncol (2002) 1.71
Positron emission tomography imaging of CD105 expression during tumor angiogenesis. Eur J Nucl Med Mol Imaging (2011) 1.70
A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol (2002) 1.68
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 1.65
Drug interactions in cancer therapy. Nat Rev Cancer (2006) 1.62
Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res (2006) 1.60
The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther (2009) 1.57
Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clin Cancer Res (2010) 1.56
Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Updat (2003) 1.54
A Study of Methadone Maintenance For Male Prisoners: 3-Month Postrelease Outcomes. Crim Justice Behav (2008) 1.54
In vivo targeting and imaging of tumor vasculature with radiolabeled, antibody-conjugated nanographene. ACS Nano (2012) 1.53
Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives. Curr Neuropharmacol (2006) 1.53
Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis. Cancer Res (2008) 1.53
Superior mesenteric vein thrombosis after colectomy for inflammatory bowel disease: a not uncommon cause of postoperative acute abdominal pain. Dis Colon Rectum (2003) 1.51
Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105. Eur J Nucl Med Mol Imaging (2011) 1.50
Flavopiridol inversely affects p21(WAF1/CIP1) and p53 and protects p21-sensitive cells from paclitaxel. Cancer Biol Ther (2002) 1.50
Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol (2003) 1.49
Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol (2008) 1.48
Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res (2008) 1.48
Buprenorphine-naloxone Treatment for Pre-release Opioid-dependent Inmates in Puerto Rico. J Addict Med (2007) 1.47
Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. BJU Int (2013) 1.47
Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study. Eur Urol (2007) 1.46
Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res (2009) 1.46
Size-selective collection of circulating tumor cells using Vortex technology. Lab Chip (2013) 1.46
Epidithiodiketopiperazines block the interaction between hypoxia-inducible factor-1alpha (HIF-1alpha) and p300 by a zinc ejection mechanism. J Biol Chem (2009) 1.44
Estrogen receptor α and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy. J Clin Endocrinol Metab (2010) 1.44
American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol (2004) 1.44
A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. BJU Int (2008) 1.41
Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol (2002) 1.40
Lack of ABC transporter autoinduction in mice following long-term exposure to imatinib. Cancer Biol Ther (2007) 1.40
Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention. Mol Cancer Res (2006) 1.40
2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy (2003) 1.40
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother (2008) 1.39
Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood (2011) 1.39
Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma. J Pharm Biomed Anal (2008) 1.39
Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. J Cancer Res Clin Oncol (2009) 1.38
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int (2009) 1.37
Melanoma. J Natl Compr Canc Netw (2009) 1.37
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur J Cancer (2009) 1.36
Positron emission tomography imaging of CD105 expression with a 64Cu-labeled monoclonal antibody: NOTA is superior to DOTA. PLoS One (2011) 1.36
In vivo tumor targeting and image-guided drug delivery with antibody-conjugated, radiolabeled mesoporous silica nanoparticles. ACS Nano (2013) 1.34
A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res (2010) 1.34
Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev Anticancer Ther (2010) 1.34
Clinical and molecular responses in lung cancer patients receiving Romidepsin. Clin Cancer Res (2008) 1.34
Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. Cancer Invest (2004) 1.33